Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: Safety and efficacy data in a series of 21 patients from Europe and the USA

K. W. Douglas, A. N. Parker, P. J. Hayden, A. Rahemtulla, A. D'Addio, R. M. Lemoli, K. Rao, M. Maris, A. Pagliuca, J. Uberti, C. Scheid, R. Noppeney, G. Cook, S. W. Bokhari, N. Worel, G. Mikala, T. Masszi, R. Taylor, J. Treisman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34 cell dose of 4.6 × 106 per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24mg/kg/day, resulting in a CD34+ cell dose of 2.12 × 106 /kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalBone Marrow Transplantation
Volume47
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Renal Insufficiency
Safety
Blood Component Removal
Autografts
JM 3100
Granulocyte Colony-Stimulating Factor
Kidney Transplantation
Disease Progression
Dialysis
Transplants
Kidney

Keywords

  • autologous HSC transplant
  • dialysis
  • kidney failure
  • myeloma
  • plerixafor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure : Safety and efficacy data in a series of 21 patients from Europe and the USA. / Douglas, K. W.; Parker, A. N.; Hayden, P. J.; Rahemtulla, A.; D'Addio, A.; Lemoli, R. M.; Rao, K.; Maris, M.; Pagliuca, A.; Uberti, J.; Scheid, C.; Noppeney, R.; Cook, G.; Bokhari, S. W.; Worel, N.; Mikala, G.; Masszi, T.; Taylor, R.; Treisman, J.

In: Bone Marrow Transplantation, Vol. 47, No. 1, 01.2012, p. 18-23.

Research output: Contribution to journalArticle

Douglas, KW, Parker, AN, Hayden, PJ, Rahemtulla, A, D'Addio, A, Lemoli, RM, Rao, K, Maris, M, Pagliuca, A, Uberti, J, Scheid, C, Noppeney, R, Cook, G, Bokhari, SW, Worel, N, Mikala, G, Masszi, T, Taylor, R & Treisman, J 2012, 'Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: Safety and efficacy data in a series of 21 patients from Europe and the USA', Bone Marrow Transplantation, vol. 47, no. 1, pp. 18-23. https://doi.org/10.1038/bmt.2011.9
Douglas, K. W. ; Parker, A. N. ; Hayden, P. J. ; Rahemtulla, A. ; D'Addio, A. ; Lemoli, R. M. ; Rao, K. ; Maris, M. ; Pagliuca, A. ; Uberti, J. ; Scheid, C. ; Noppeney, R. ; Cook, G. ; Bokhari, S. W. ; Worel, N. ; Mikala, G. ; Masszi, T. ; Taylor, R. ; Treisman, J. / Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure : Safety and efficacy data in a series of 21 patients from Europe and the USA. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 1. pp. 18-23.
@article{97d550d3e10e4729a79f6161cde1ad3b,
title = "Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: Safety and efficacy data in a series of 21 patients from Europe and the USA",
abstract = "We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34 cell dose of 4.6 × 106 per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24mg/kg/day, resulting in a CD34+ cell dose of 2.12 × 106 /kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group.",
keywords = "autologous HSC transplant, dialysis, kidney failure, myeloma, plerixafor",
author = "Douglas, {K. W.} and Parker, {A. N.} and Hayden, {P. J.} and A. Rahemtulla and A. D'Addio and Lemoli, {R. M.} and K. Rao and M. Maris and A. Pagliuca and J. Uberti and C. Scheid and R. Noppeney and G. Cook and Bokhari, {S. W.} and N. Worel and G. Mikala and T. Masszi and R. Taylor and J. Treisman",
year = "2012",
month = "1",
doi = "10.1038/bmt.2011.9",
language = "English",
volume = "47",
pages = "18--23",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure

T2 - Safety and efficacy data in a series of 21 patients from Europe and the USA

AU - Douglas, K. W.

AU - Parker, A. N.

AU - Hayden, P. J.

AU - Rahemtulla, A.

AU - D'Addio, A.

AU - Lemoli, R. M.

AU - Rao, K.

AU - Maris, M.

AU - Pagliuca, A.

AU - Uberti, J.

AU - Scheid, C.

AU - Noppeney, R.

AU - Cook, G.

AU - Bokhari, S. W.

AU - Worel, N.

AU - Mikala, G.

AU - Masszi, T.

AU - Taylor, R.

AU - Treisman, J.

PY - 2012/1

Y1 - 2012/1

N2 - We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34 cell dose of 4.6 × 106 per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24mg/kg/day, resulting in a CD34+ cell dose of 2.12 × 106 /kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group.

AB - We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional means (plerixafor used up-front for 4 patients). For 15 patients, the plerixafor dose was reduced to 0.16 mg/kg/day, with a subsequent dose increase in one case to 0.24 mg/kg/day. The remaining six patients received a standard plerixafor dosage at 0.24 mg/kg/day. Scheduling of plerixafor and apheresis around dialysis was generally straightforward. Following plerixafor administration, all patients underwent apheresis. A median CD34 cell dose of 4.6 × 106 per kg was achieved after 1 (n=7), 2 (n=10), 3 (n=3) or 4 (n=1) aphereses. Only one patient failed to achieve a sufficient cell dose for transplant: she subsequently underwent delayed re-mobilisation using G-CSF with plerixafor 0.24mg/kg/day, resulting in a CD34+ cell dose of 2.12 × 106 /kg. Sixteen patients experienced no plerixafor toxicities; five had mild-to-moderate gastrointestinal symptoms that did not prevent apheresis. Fifteen patients have progressed to autologous transplant, of whom 12 remain alive without disease progression. Two patients recovered endogenous renal function post autograft, and a third underwent successful renal transplantation. Plerixafor is highly effective in mobilising PBSC in this difficult patient group.

KW - autologous HSC transplant

KW - dialysis

KW - kidney failure

KW - myeloma

KW - plerixafor

UR - http://www.scopus.com/inward/record.url?scp=84855749342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855749342&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.9

DO - 10.1038/bmt.2011.9

M3 - Article

C2 - 21358693

AN - SCOPUS:84855749342

VL - 47

SP - 18

EP - 23

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -